Literature DB >> 1661316

Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.

B S Peters1, E J Beck, S Anderson, D Coleman, R Coker, J Main, C Migdal, J R Harris, A J Pinching.   

Abstract

Among 347 AIDS patients seen at St Mary's Hospital, London between 1983 and 1989, cytomegalovirus (CMV) disease was observed in 75 (22%). Of these, 58 (77%) had CMV retinitis, 26 (35%) CMV colitis, and 12 (16%) had CMV infection diagnosed at other sites. Relapse occurred in 71%. A favourable response to the use of ganciclovir as induction therapy for CMV retinitis was observed in 92%. Relapse of CMV retinitis occurred in 54% at a median time of 97 days. Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1.0 x 10(9)/l and 48% less than 0.5 x 10(9)/l at some stage of therapy. Thrombocytopenia was also common, and platelet counts of less than 50 x 10(9)/l occurred in 43% patients on ganciclovir. The concurrent use of zidovudine made the development of severe neutropenia and thrombocytopenia more likely. Median survival following the diagnosis of CMV disease increased from 5-8 months between 1984 and 1987, to over 12 months in 1988. Patients with CMV colitis had a worse prognosis than patients with CMV retinitis, with median survival of 4.5 and 7 months respectively. In conclusion, CMV is an important opportunist infection in AIDS and both the disease and its treatment cause considerable morbidity. Hence, it is important to develop more effective and less toxic forms of therapy for CMV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661316     DOI: 10.1016/0163-4453(91)91987-9

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  13 in total

1.  Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine Cohort, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

Authors:  C Binquet; F Saillour; N Bernard; M B Rougier; F Leger; F Bonnal; F Dabis
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

Review 2.  Management of CMV retinitis in HIV infected patients.

Authors:  C Katlama
Journal:  Genitourin Med       Date:  1997-06

3.  Fluorescence in situ hybridization with cosmid clones for the detection of human cytomegalovirus DNA in peripheral blood leukocytes.

Authors:  H Hackstein; G Jahn; H Kirchner; G Bein
Journal:  Histochem Cell Biol       Date:  1996-08       Impact factor: 4.304

Review 4.  Cytomegalovirus-induced thrombocytopenia in an immunocompetent adult.

Authors:  M J Eisenberg; B Kaplan
Journal:  West J Med       Date:  1993-05

5.  Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus.

Authors:  J G Jacobson; T E Renau; M R Nassiri; D G Sweier; J M Breitenbach; L B Townsend; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Cytomegalovirus colitis in individuals without apparent cause of immunodeficiency.

Authors:  F H Ng; T N Chau; T C Cheung; C Kng; S Y Wong; W F Ng; K C Lee; E Chan; S T Lai; W C Yuen; C M Chang
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

7.  Retinal findings in Malawian patients with AIDS.

Authors:  S Lewallen; J Kumwenda; D Maher; A D Harries
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

8.  Enterocolic fistula: A rare presentation of cytomegalovirus infection.

Authors:  Richdeep S Gill; Geoffrey Taylor; Robert M Penner; Sarvesh Logsetty
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

9.  Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.

Authors:  H Manji; M J Harrison; J M Round; D A Jones; S Connolly; C J Fowler; I Williams; I V Weller
Journal:  J Neurol       Date:  1993-09       Impact factor: 4.849

Review 10.  Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.

Authors:  B S Peters; E Carlin; R J Weston; S J Loveless; J Sweeney; J Weber; J Main
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.